MX346185B - Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. - Google Patents
Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.Info
- Publication number
- MX346185B MX346185B MX2013005442A MX2013005442A MX346185B MX 346185 B MX346185 B MX 346185B MX 2013005442 A MX2013005442 A MX 2013005442A MX 2013005442 A MX2013005442 A MX 2013005442A MX 346185 B MX346185 B MX 346185B
- Authority
- MX
- Mexico
- Prior art keywords
- cognitive impairment
- compositions
- methods
- pyridazine derivatives
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41397110P | 2010-11-15 | 2010-11-15 | |
| PCT/US2011/060854 WO2012068161A1 (en) | 2010-11-15 | 2011-11-15 | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013005442A MX2013005442A (es) | 2013-10-03 |
| MX346185B true MX346185B (es) | 2017-03-10 |
Family
ID=46084380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005442A MX346185B (es) | 2010-11-15 | 2011-11-15 | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
| MX2017003111A MX383953B (es) | 2010-11-15 | 2011-11-15 | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003111A MX383953B (es) | 2010-11-15 | 2011-11-15 | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9145372B2 (enExample) |
| EP (2) | EP3034079B1 (enExample) |
| JP (1) | JP5916746B2 (enExample) |
| CN (1) | CN103313712B (enExample) |
| AU (1) | AU2011328993B2 (enExample) |
| BR (1) | BR112013012062B1 (enExample) |
| CA (1) | CA2818025A1 (enExample) |
| DK (2) | DK3034079T3 (enExample) |
| EA (1) | EA027840B1 (enExample) |
| MX (2) | MX346185B (enExample) |
| NO (1) | NO3034079T3 (enExample) |
| WO (1) | WO2012068161A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011328993B2 (en) | 2010-11-15 | 2017-03-02 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| WO2012071584A2 (en) * | 2010-11-26 | 2012-05-31 | Brigham And Women's Hospital, Inc. | Method for assessing repetitive head injuries with tow-dimensional magnetic resonance spectorscopy |
| CA2885148A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
| WO2014078377A1 (en) * | 2012-11-14 | 2014-05-22 | Agenebio, Inc. | Methods and compositions for treating schizophrenia |
| EP4032889B1 (en) | 2013-12-20 | 2026-05-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3310785B1 (en) | 2015-06-19 | 2024-11-20 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| TWI697485B (zh) | 2015-07-21 | 2020-07-01 | 日商捷恩智股份有限公司 | 含唑啉環的化合物、含有其的電子輸送/注入層用材料、使用其的有機電致發光元件、顯示裝置及照明裝置 |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN113840569B (zh) | 2019-03-19 | 2025-01-07 | 剑桥认知有限公司 | 诊断精神病症和推荐用于精神病症的治疗的方法和用途 |
| AU2022349463A1 (en) * | 2021-09-24 | 2024-03-14 | Xenon Pharmaceuticals Inc. | Pyridinyl derivatives as sodium channel activators |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| NL7305644A (enExample) | 1972-04-20 | 1973-10-23 | ||
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Janssen Pharmaceutica, Naamloze Vennootschap | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| ATE180475T1 (de) | 1990-09-21 | 1999-06-15 | Rohm & Haas | Dihydropyridazinone und pyridazinone als fungizide |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1992020682A1 (en) | 1991-05-24 | 1992-11-26 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (enExample) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| ATE167057T1 (de) | 1994-03-02 | 1998-06-15 | Akzo Nobel Nv | Sublinguales oder bukkales arzneimittel |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| WO1999025353A1 (en) | 1997-11-13 | 1999-05-27 | Merck Sharp & Dohme Limited | Therapeutic uses of triazolo-pyridazine derivatives |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| CA2349700A1 (en) | 1998-11-12 | 2000-05-18 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| US6677330B1 (en) | 1999-03-03 | 2004-01-13 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| IL157465A0 (en) | 2001-03-01 | 2004-03-28 | Pfizer Products Inc Pfizer Pro | Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| WO2003025122A2 (en) | 2001-08-13 | 2003-03-27 | University Of Kentucky Research Foundation | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| CA2473536A1 (en) | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| CA2495285A1 (en) * | 2002-08-13 | 2004-02-19 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for gaba receptors |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| MXPA05005398A (es) | 2002-11-22 | 2006-03-09 | Univ Johns Hopkins | Meta para terapia de deterioro cognitivo. |
| AU2004316119B2 (en) | 2003-10-22 | 2008-04-24 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies |
| US20060079582A1 (en) | 2004-09-23 | 2006-04-13 | Jeffrey Jonas | Memantine for the treatment of childhood behavioral disorders |
| ATE402707T1 (de) | 2004-10-12 | 2008-08-15 | Hoffmann La Roche | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen |
| NZ554439A (en) | 2004-10-20 | 2009-09-25 | Hoffmann La Roche | Imidazo-benzodiazepine derivatives |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US7595395B2 (en) | 2005-05-16 | 2009-09-29 | Wisys Technology Foundation | Gabaergic agents to treat memory deficits |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010036553A1 (en) * | 2008-09-24 | 2010-04-01 | E. I. Du Pont De Nemours And Company | Fungicidal pyridazines |
| BRPI0920515B1 (pt) | 2008-09-25 | 2018-03-20 | Vive Nano, Inc. | Composição compreendendo nanopartícula de polímero e composto ativo agrícola |
| EP2419401A2 (en) | 2009-04-17 | 2012-02-22 | XenoPort, Inc. | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS |
| WO2011085406A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| MX2013005443A (es) | 2010-11-15 | 2013-10-07 | Agenebio Inc | Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo. |
| AU2011328993B2 (en) | 2010-11-15 | 2017-03-02 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| JPWO2012161133A1 (ja) * | 2011-05-20 | 2014-07-31 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| WO2014039920A1 (en) | 2012-09-10 | 2014-03-13 | Lewin Matthew R | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| EP4032889B1 (en) | 2013-12-20 | 2026-05-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2011
- 2011-11-15 AU AU2011328993A patent/AU2011328993B2/en not_active Ceased
- 2011-11-15 US US13/885,569 patent/US9145372B2/en not_active Expired - Fee Related
- 2011-11-15 MX MX2013005442A patent/MX346185B/es active IP Right Grant
- 2011-11-15 DK DK15187794.1T patent/DK3034079T3/en active
- 2011-11-15 WO PCT/US2011/060854 patent/WO2012068161A1/en not_active Ceased
- 2011-11-15 EP EP15187794.1A patent/EP3034079B1/en active Active
- 2011-11-15 CN CN201180063261.2A patent/CN103313712B/zh not_active Expired - Fee Related
- 2011-11-15 EA EA201390712A patent/EA027840B1/ru not_active IP Right Cessation
- 2011-11-15 CA CA2818025A patent/CA2818025A1/en not_active Abandoned
- 2011-11-15 NO NO15187794A patent/NO3034079T3/no unknown
- 2011-11-15 JP JP2013539003A patent/JP5916746B2/ja active Active
- 2011-11-15 EP EP11841746.8A patent/EP2640391B1/en active Active
- 2011-11-15 MX MX2017003111A patent/MX383953B/es unknown
- 2011-11-15 DK DK11841746.8T patent/DK2640391T3/da active
- 2011-11-15 BR BR112013012062-2A patent/BR112013012062B1/pt not_active IP Right Cessation
-
2015
- 2015-09-18 US US14/858,959 patent/US9801879B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2640391B1 (en) | 2015-11-11 |
| US20160008357A1 (en) | 2016-01-14 |
| CN103313712B (zh) | 2016-10-26 |
| EP3034079A1 (en) | 2016-06-22 |
| CN103313712A (zh) | 2013-09-18 |
| US20130237545A1 (en) | 2013-09-12 |
| DK3034079T3 (en) | 2018-02-05 |
| DK2640391T3 (da) | 2016-02-15 |
| MX2013005442A (es) | 2013-10-03 |
| EP3034079B1 (en) | 2018-01-10 |
| AU2011328993A1 (en) | 2013-06-06 |
| MX383953B (es) | 2025-03-14 |
| EA027840B1 (ru) | 2017-09-29 |
| EP2640391A1 (en) | 2013-09-25 |
| AU2011328993B2 (en) | 2017-03-02 |
| EA201390712A1 (ru) | 2013-11-29 |
| US9145372B2 (en) | 2015-09-29 |
| JP5916746B2 (ja) | 2016-05-11 |
| CA2818025A1 (en) | 2012-05-24 |
| BR112013012062B1 (pt) | 2020-06-02 |
| NO3034079T3 (enExample) | 2018-06-09 |
| JP2013542267A (ja) | 2013-11-21 |
| US9801879B2 (en) | 2017-10-31 |
| WO2012068161A1 (en) | 2012-05-24 |
| BR112013012062A2 (pt) | 2016-08-16 |
| EP2640391A4 (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383953B (es) | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| CO2018009889A2 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| MX2016007808A (es) | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo. | |
| MX350890B (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina. | |
| BR112013033417A2 (pt) | compostos terapêuticos e métodos relacionados de uso | |
| UY35628A (es) | ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?. | |
| GT201300206A (es) | Imidazo(5,1-f)(1,2,4)triazinas para el tratamiento de transtornos neurológicos | |
| BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
| CL2010000129A1 (es) | Compuestos derivados de benzazepinas fusionadas sustituidas, moduladores del receptor de acetilcolina; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de trastornos del snc tales como esquizofrenia, demencia, enfermedad del alzheimer, esclerosis multiple, entre otras. | |
| CL2009001212A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras. | |
| MX2017015752A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. | |
| NI202000074A (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| MX2019007338A (es) | Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo. | |
| EA202190076A1 (ru) | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений | |
| CY1123396T1 (el) | Αγωγες συνδυασμου περιλαμβανοντας ιμιδαζοπυραζινονες για την αγωγη ψυχιατρικων και/ή γνωσιακων διαταραχων | |
| AR061637A1 (es) | Composiciones y metodos de tratamiento de trastornos del snc | |
| CO2023007617A2 (es) | Prevención y/o tratamiento de enfermedades del snc | |
| CL2011000865A1 (es) | Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras. | |
| CL2012000539A1 (es) | Compuestos derivados de acido 3-(morfolin-4-il)-propionico, moduladores de s1p; composicion farmaceutica; utiles en el tratamiento, alivio o prvencion de enfermedades del sistema nervioso central, tales como trastornos neurodegenerativas, enfermedades de alzheimer, depresion mayor, autismo, entre otras. | |
| EA201892113A1 (ru) | Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов | |
| CL2012000650A1 (es) | Compuestos derivados de dihidro- benzocicloalquiloximetil- oxazolopirimidonas sustituidas, moduladores alosterocos de receptores metabortropicos de glutamato ( mglur); composicion famaceutica que los comprende; y uso para el tratamiento y/o prevencion de enfermedades asociadas del snc, como ansiedad, migraña, dolor, entre otras. | |
| EA201691290A1 (ru) | Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения | |
| CL2009000149A1 (es) | Compuestos heterociclos que incluyen un grupo ciclobutoxi sustituido ligandos del receptor h3 composicion farmaceutica que los comprende utiles para tratar enfermedades del sistema nervioso central, tales como deterioro cognitivo leve, alzheimer, trastornos de la memoria, enfermedad de parkinson, esquizofrenia y demencia. | |
| BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |